-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Sihuan Pharmaceutical announced on the evening of April 18 that Hainan Sihuan Pharmaceutical, a wholly-owned subsidiary of the company, plans to sell the entire issued share capital of Beijing Xuansheng for 118 million yuan, and the net proceeds from the sale will be used for the group general working capital
.
Regarding the reason for the sale of Beijing Xuansheng, Sihuan Pharmaceutical stated that Beijing Xuansheng’s main products have potential peer competition with Xuanzhu Bio in terms of product indications
.
Recently, there has also been news in the industry that Tianjing Bio is considering options such as merging with another company or selling shares linked to specific pharmaceutical partnerships
.
The company mainly focuses on the early discovery, drug development and commercialization of innovative biological drugs in the field of tumor immunity and autoimmune diseases.
So far, no products have been successfully launched
.
Up to now, there are 1 product to be declared for listing, 2 Phase III/registration clinical trials, 7 Phase II trials, and 8 Phase I trials in the Tianjing Biological pipeline
.
On April 2, Renfu Pharmaceutical issued an announcement that in order to focus on the main business and optimize the company's business structure and asset-liability structure, the company and Hongtai Group signed the "Attachment Regarding the 7.
85% Shares of Tianfeng Securities Co.
, Ltd.
" on March 31, 2022.
Conditional Share Transfer Agreement", the company intends to transfer 680 million shares of Tianfeng Securities to Hubei Hongtai Group Co.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2.
124 billion
.
At the end of March, Wisdom Medicine announced that it planned to sell 100% of the shares of Quantum Hi-Tech
.
The latter's main product is prebiotics
.
The transaction price of this transaction is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
Regarding the sale of assets, Wisdom Pharma said that by setting out the Quantum Hi-Tech and prebiotic businesses, it will help the company focus on the main business of CXO, while optimizing the company's asset and liability structure
.
In addition, since 2022, a large number of pharmaceutical companies such as Xinrui Pharmaceutical, Tonghua Dongbao, Qiangsheng Pharmaceutical, Hefei Lifang Pharmaceutical, Xianju Pharmaceutical, Asia Pacific Pharmaceutical, and Shuangcheng Pharmaceutical have opened the "selling, selling and selling" model to accelerate the "return of blood".
, gather resources and rearrange them
.
Not only domestic pharmaceutical companies, but also multinational pharmaceutical companies are also starting a "slimming model"
.
In February, it was reported that private equity firms Blackstone Group and The Carlyle Group may join forces to buy Sandoz, a generic drug company owned by Novartis, for $25 billion
.
Regarding Novartis' possible move to spin off Sandoz, some analysts believe that it is an adjustment made by Novartis based on its corporate development strategy
.
There are also analysts who believe that after the sale or spin-off of Sandoz, Novartis will obtain higher profits and may generate higher returns on capital; The transfer of the production and sales rights of Colabituto preparations in mainland China and the entire equity of the production company producing the preparations is expected to be completed in August 2022 after approval by the relevant Chinese authorities.
The transfer profits from the share transfer are expected to be Included in March 2023
.
From the perspective of the entire pharmaceutical environment, the current pharmaceutical market competition has become more and more intense, and pharmaceutical companies are facing increasing pressures from various aspects, including price reduction pressure, competition pressure from similar products, and commercialization pressure
.
Under the consideration of cost reduction, it is also reasonable for companies to choose to divest non-core businesses
.
The industry believes that the competition in the pharmaceutical market will become more and more fierce in 2022
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Regarding the reason for the sale of Beijing Xuansheng, Sihuan Pharmaceutical stated that Beijing Xuansheng’s main products have potential peer competition with Xuanzhu Bio in terms of product indications
.
Recently, there has also been news in the industry that Tianjing Bio is considering options such as merging with another company or selling shares linked to specific pharmaceutical partnerships
.
The company mainly focuses on the early discovery, drug development and commercialization of innovative biological drugs in the field of tumor immunity and autoimmune diseases.
So far, no products have been successfully launched
.
Up to now, there are 1 product to be declared for listing, 2 Phase III/registration clinical trials, 7 Phase II trials, and 8 Phase I trials in the Tianjing Biological pipeline
.
On April 2, Renfu Pharmaceutical issued an announcement that in order to focus on the main business and optimize the company's business structure and asset-liability structure, the company and Hongtai Group signed the "Attachment Regarding the 7.
85% Shares of Tianfeng Securities Co.
, Ltd.
" on March 31, 2022.
Conditional Share Transfer Agreement", the company intends to transfer 680 million shares of Tianfeng Securities to Hubei Hongtai Group Co.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2.
124 billion
.
At the end of March, Wisdom Medicine announced that it planned to sell 100% of the shares of Quantum Hi-Tech
.
The latter's main product is prebiotics
.
The transaction price of this transaction is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
Regarding the sale of assets, Wisdom Pharma said that by setting out the Quantum Hi-Tech and prebiotic businesses, it will help the company focus on the main business of CXO, while optimizing the company's asset and liability structure
.
In addition, since 2022, a large number of pharmaceutical companies such as Xinrui Pharmaceutical, Tonghua Dongbao, Qiangsheng Pharmaceutical, Hefei Lifang Pharmaceutical, Xianju Pharmaceutical, Asia Pacific Pharmaceutical, and Shuangcheng Pharmaceutical have opened the "selling, selling and selling" model to accelerate the "return of blood".
, gather resources and rearrange them
.
Not only domestic pharmaceutical companies, but also multinational pharmaceutical companies are also starting a "slimming model"
.
In February, it was reported that private equity firms Blackstone Group and The Carlyle Group may join forces to buy Sandoz, a generic drug company owned by Novartis, for $25 billion
.
Regarding Novartis' possible move to spin off Sandoz, some analysts believe that it is an adjustment made by Novartis based on its corporate development strategy
.
There are also analysts who believe that after the sale or spin-off of Sandoz, Novartis will obtain higher profits and may generate higher returns on capital; The transfer of the production and sales rights of Colabituto preparations in mainland China and the entire equity of the production company producing the preparations is expected to be completed in August 2022 after approval by the relevant Chinese authorities.
The transfer profits from the share transfer are expected to be Included in March 2023
.
From the perspective of the entire pharmaceutical environment, the current pharmaceutical market competition has become more and more intense, and pharmaceutical companies are facing increasing pressures from various aspects, including price reduction pressure, competition pressure from similar products, and commercialization pressure
.
Under the consideration of cost reduction, it is also reasonable for companies to choose to divest non-core businesses
.
The industry believes that the competition in the pharmaceutical market will become more and more fierce in 2022
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
